A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. - Wang, Yuanyuan; Guo, Haoyue; Han, Ruoshuang; Wu, Yuhan; He, Taiping; Diao, Meng; Xiong, Anwen; Zhou, Fei; Cheng, Lei; Zhao, Chao; Li, Xuefei; Zhou, Caicun (Cellular Oncology (2211-3428), 2026)